Virological failure of intralesional cidofovir therapy in recurrent respiratory papillomatosis is not associated with genetic or epigenetic changes of HPV11: Complete genome comparison of sequential isolates

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 356-358

  Gáll, Tamás ^a   Kis, Andrea ^a   Fehér, Eniko ^a   Gergely, Lajos ^a   Szarka, Krisztina ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antiviral resistance; Complete genome; Laryngeal papillomatosis; LCR methylation; Therapeutic response

Indexed keywords

BISULFITE; CIDOFOVIR; DNA FRAGMENT; INTERFERON;

ARTICLE; BASE PAIRING; BINDING SITE; CPG ISLAND; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN PAPILLOMAVIRUS TYPE 11; LARYNX PAPILLOMATOSIS; METHYLATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; VIRUS GENOME; VIRUS ISOLATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CYTOSINE; DNA METHYLATION; DNA, VIRAL; EPIGENESIS, GENETIC; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 11; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RESPIRATORY TRACT INFECTIONS; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

HUMAN PAPILLOMAVIRUS TYPE 11;

EID: 80054867486     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.09.007     Document Type: Article

References (28)

1. Abdulkarim B., Bourhis J. Antiviral approaches for cancers related to Epstein-Barr virus and human papillomavirus. Lancet Oncol. 2001, 2:622-630.
2. Abdulkarim B., Sabri S., Deutsch E., Chagraoui H., Maggiorella L., Thierry J., Eschwege F., Vainchenker W., Chouaïb S., Bourhis J. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002, 21:2334-2346.
3. Akst L.M., Lee W., Discolo C., Knott D., Younes A., Koltai P.J. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 2003, 129:841-846.
4. Andrei G., Snoeck R., Piette J., Delvenne P., De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 1998, 10:523-531.
5. Avidano M.A., Singleton G.T. Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis. Otolaryngol. Head Neck Surg. 1995, 112:197-202.
6. Chadha N., James A. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol. Head Neck Surg. 2007, 136:863-869.
7. Chetri D.K., Shapiro N.L. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch. Otolaryngol. Head Neck Surg. 2003, 129:1081-1085.
8. Derkay C.S. Recurrent respiratory papillomatosis. Laryngoscope 2001, 111:57-69.
9. Dickens P., Srivastava G., Loke S.L., Larkin S. Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J. Pathol. 1991, 165:243-246.
10. Donne A.J., Hampson L., He X.T., Rothera M.P., Homer J.J., Hampson I.N. Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck 2009, 31:893-901.
11. Johnson J.A., Gangemi J.D. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob. Agents Chemother. 1999, 43:1198-1205.
12. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., Wiley D.J., Bernard H.U. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 2004, 78:12762-12772.
13. Lott D.G., Krakovitz P.R. Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2009, 119:567-570.
14. Major T., Sziklai I., Czeglédy J., Gáll T., Gergely L., Szarka K. Follow-up of HPV DNA copy number in cidofovir therapy of recurrent respiratory papillomatosis. Anticancer Res. 2008, 28:2169-2174.
15. Mayrand M.H., Coutlée F., Hankins C., Lapointe N., Forest P., de Ladurantaye M., Roger M. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J. Clin. Microbiol. 2000, 38:3388-3393.
16. Pisarev V.M., Lee S.H., Connelly M.C., Fridland A. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol. Pharmacol. 1997, 52:63-68.
17. Pransky S.M., Magit A.E., Kearns D.B., Kang D.R., Duncan N.O. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg. 1999, 125:1143-1148.
18. Pransky S.M., Brewster D.F., Magit A.E., Kearns D.B. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 2000, 126:1239-1243.
19. Pransky S.M., Kang D.R. Tumors of the larynx, trachea and bronchi. Pediatric Otolaryngology 2003, 1558-1572. WB Saunders CO, Philadelphia, PA. C.D. Bluestone, S.E. Stool, M.A. Kenna (Eds.).
20. Reeves W.C., Ruparelia S.S., Swanson K.I., Derkay C.S., Marcus A., Unger E.R. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 2003, 129:976-982.
21. Safrin S., Cherrington J., Jaffe H.S. Clinical uses of cidofovir. Rev. Med. Virol. 1997, 7:145-156.
22. Snoeck R., Wellens W., Desloovere C., Van Ranst M., Naesens L., De Clercq E., Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J. Med. Virol. 1998, 54:219-225.
23. Steinau M., Swan D.C., Onyekwuluje J.M., Brooks J.T., Vellozzi C., Unger E.R., Study Investigators S.U.N. Differences and changes in human papillomavirus 16 variant status in human immunodeficiency virus-positive adults are not uncommon. J. Gen. Virol. 2010, 91:2068-2072.
24. Tanna N., Sidell D., Joshi A.S., Bielamowicz S.A. Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. Arch. Otolaryngol. Head Neck Surg. 2008, 134:497-500.
25. Van Cutsem E., Snoeck R., Van Ranst M., Fiten P., Opdenakker G., Geboes K., Janssens J., Rutgeerts P., Vantrappen G., de Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir). J. Med. Virol. 1995, 45:230-235.
26. Wilson W.R., Hashemiyoon R., Hawrych A. Intralesional cidofovir for recurrent laryngeal papillomas: preliminary report. Ear Nose Throat J. 2000, 79:236-238. , 240.
27. Xi L.F., Koutsky L.A., Castle P.E., Edelstein Z.R., Hulbert A., Schiffman M., Kiviat N.B. Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. J. Infect. Dis. 2010, 202:1667-1670.
28. Xiong X., Smith J.L., Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 41:594-599.